FY2029 Earnings Forecast for SAGE Issued By Wedbush

Sage Therapeutics, Inc. (NASDAQ:SAGE) – Analysts at Wedbush issued their FY2029 EPS estimates for Sage Therapeutics in a report issued on Thursday, January 23rd. Wedbush analyst L. Chico forecasts that the biopharmaceutical company will post earnings per share of $0.35 for the year. Wedbush currently has a “Neutral” rating and a $8.00 target price on the stock. The consensus estimate for Sage Therapeutics’ current full-year earnings is ($6.47) per share.

Sage Therapeutics (NASDAQ:SAGE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) EPS for the quarter, missing analysts’ consensus estimates of ($1.52) by ($0.01). Sage Therapeutics had a negative net margin of 317.29% and a negative return on equity of 50.29%. The firm had revenue of $11.87 million for the quarter, compared to analysts’ expectations of $10.80 million. During the same period in the previous year, the company earned ($2.81) EPS. The company’s revenue was up 337.1% on a year-over-year basis.

A number of other equities research analysts have also recently commented on the stock. Robert W. Baird decreased their target price on shares of Sage Therapeutics from $13.00 to $9.00 and set a “neutral” rating for the company in a research report on Wednesday, October 9th. Bank of America decreased their target price on shares of Sage Therapeutics from $11.00 to $6.00 and set an “underperform” rating for the company in a research report on Wednesday, October 9th. Royal Bank of Canada raised shares of Sage Therapeutics from an “underperform” rating to a “sector perform” rating and set a $4.00 price target for the company in a report on Thursday, November 21st. HC Wainwright reaffirmed a “neutral” rating and issued a $14.00 price target on shares of Sage Therapeutics in a report on Wednesday, November 20th. Finally, Oppenheimer decreased their price target on shares of Sage Therapeutics from $9.00 to $8.00 and set a “market perform” rating for the company in a report on Wednesday, October 30th. Three investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $10.53.

Sage Therapeutics Stock Up 1.1 %

NASDAQ:SAGE opened at $7.10 on Friday. Sage Therapeutics has a 52 week low of $4.62 and a 52 week high of $27.67. The firm has a 50 day moving average of $5.83 and a 200 day moving average of $7.34. The stock has a market capitalization of $434.33 million, a price-to-earnings ratio of -1.27 and a beta of 0.91.

Institutional Trading of Sage Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SAGE. Renaissance Technologies LLC grew its position in Sage Therapeutics by 1,476.6% during the second quarter. Renaissance Technologies LLC now owns 553,396 shares of the biopharmaceutical company’s stock valued at $6,010,000 after buying an additional 518,296 shares during the period. State Street Corp grew its position in Sage Therapeutics by 18.2% during the third quarter. State Street Corp now owns 2,926,239 shares of the biopharmaceutical company’s stock valued at $21,127,000 after buying an additional 451,377 shares during the period. Cubist Systematic Strategies LLC grew its position in Sage Therapeutics by 831.2% during the second quarter. Cubist Systematic Strategies LLC now owns 489,089 shares of the biopharmaceutical company’s stock valued at $5,312,000 after buying an additional 436,566 shares during the period. Squarepoint Ops LLC grew its position in Sage Therapeutics by 1,112.0% during the second quarter. Squarepoint Ops LLC now owns 313,407 shares of the biopharmaceutical company’s stock valued at $3,404,000 after buying an additional 287,549 shares during the period. Finally, RTW Investments LP grew its position in Sage Therapeutics by 2.0% during the third quarter. RTW Investments LP now owns 5,591,700 shares of the biopharmaceutical company’s stock valued at $40,372,000 after buying an additional 111,123 shares during the period. Institutional investors and hedge funds own 99.22% of the company’s stock.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.